Source link : https://www.yourblogdomain.com/2024/12/19/t-dxd-effective-in-hr-her2-low-bc-after-endocrine-failure/
Source link : https://www.newshealth.biz/health-news/t-dxd-effective-in-hr-her2-low-bc-after-endocrine-failure/ New analysis of the DESTINY-Breast06 trial demonstrated that trastuzumab deruxtecan (T-DXd) provides meaningful clinical benefit regardless of time to progression on prior endocrine therapy, offering a promising option for patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2 (HER2) low or ultra-low metastatic breast cancer. The findings, presented at […]
Author : yourblogdomain
Publish date : 2024-12-19 12:29:56
Copyright for syndicated content belongs to the linked Source.
inNews